Office of Research & Development |
|
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01BX002301-05 |
| Title: | Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival |
| Principal Investigator: | Ann Richmond |
| Location: | Nashville, TN |
| Congressional District Code: | 5 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | January 2018 - December 2021 |
| FY 2021 Funding Amount: | $156,800 |
| Total Award Amount (all years): |
$732,643 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: ABSTRACT: Metastatic melanoma is one of the fastest growing tumor types in the US, one of the top 5 cancers among Veterans, and is also one of the most challenging malignancies to treat. Currently immune therapies targeting the check-point inhibitors such as CTLA-4 and/or PD-1 can enhance the T cell response to tumor an these inhibitors have shown great success and as a result have moved to first line standard of care for most metastatic melanoma patients. Ipilimumab (targeting CTLA-4) combined... |